Construction method of tumor organoid xenotransplantation model, xenotransplantation tumor model and application
By using xenografts to perform xenografts using active growth stages, the problems of long construction cycles and slow growth rates of tumor xenograft models are solved, and faster model construction and more accurate drug efficacy testing are achieved.
Patent Information
- Application Number
- CN202410952879.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-08
AI Technical Summary
In the existing methods for constructing tumor xenograft models, the organoid inoculation volume is large and the growth rate is slow, resulting in a long construction cycle and it is difficult to meet the needs of rapid research and development, especially certain special cancers such as liver cancer, ER-positive breast cancer, leukemia, and lymph It is difficult to build models of tumors and prostate cancer.
The growth active stage passage cells collected during in vitro subculture of tumor organoids were used as seed cells. The seed cell mixture was obtained by resuspending and inoculating them to mice, which increased the inoculation success rate and growth rate and shortened the construction cycle.
It significantly improves the growth rate and construction cycle of xenograft models, shortens the R&D cycle, enhances the clinical relevance and application value of the model, and can more accurately reflect the efficacy of tumor drugs.
Smart Images

Figure CN118901667A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biological tissue engineering technology, for example, to a method for constructing a tumor organoid xenograft model and a xenograft tumor model and its application. Background Art
[0002] Patient-derived tumor xenograft models (PDX models) can retain the genetic characteristics and heterogeneity of the tumor. However, the process from surgery to successful PDX modeling takes 2 to 3 months, and drug sensitivity testing must wait until the scaled-up second-generation PDX modeling is successful. Therefore, it takes at least 4 to 6 months, which shows that the construction cycle is long. In addition, there are problems such as low detection throughput and high modeling failure rate, especially for some special cancers such as liver cancer, ER-positive breast cancer, leukemia, lymphoma, and prostate cancer, which are difficult to construct into PDX. In addition, PDX models also have problems such as the tumor microenvironment is easily replaced by mouse extracellular matrix, which affects basic research on tumors.
[0003] The organoid-derived xenograft model (PDOX) is a xenograft tumor model that first obtains tissue samples from the patient's body, cultures them into organoids in vitro, and then transplants the cultured organoids subcutaneously into immunodeficient mice.
[0004] Compared with the construction of patient-derived tumor xenograft models (PDX), the success rate of PDOX construction has been improved and the modeling cycle has been shortened due to the improved success rate of organoid culture technology. At the same time, PDOX models are also easier to genetically modify and have a wider range of applications.
[0005] In the process of implementing the embodiments of the present disclosure, it was found that there are at least the following problems in the related art: In the existing PDOX construction method, the amount of organoid inoculation is large (10 6 The xenotransplantation model has a slow growth rate and the construction cycle needs to be further shortened to further shorten the R&D cycle. Summary of the invention
[0006] In order to provide a basic understanding of some aspects of the disclosed embodiments, a brief summary is given below. The summary is not an extensive review, nor is it intended to identify key / critical elements or delineate the scope of protection of these embodiments, but rather serves as a prelude to the detailed description that follows.
[0007] The disclosed embodiments provide a method for constructing a tumor organoid xenograft model, a xenograft tumor model and applications thereof, so as to increase the growth rate of the xenograft model and further shorten the construction cycle and the research and development cycle.
[0008] In some embodiments, the method for constructing the tumor organoid xenograft model includes: obtaining actively growing passage cells; wherein the actively growing passage cells are obtained by digesting the tumor organoids collected when the tumor organoids are cultured to the active growth stage during in vitro passage culture; resuspending the actively growing passage cells to obtain an inoculated cell mixture; and inoculating the inoculated cell mixture into mice.
[0009] In some embodiments, the xenograft tumor model is constructed by the aforementioned method for constructing a tumor organoid xenograft model.
[0010] In some embodiments, the aforementioned xenograft tumor model is used in the evaluation of the efficacy of tumor drugs.
[0011] The method for constructing a tumor organoid xenograft model and a xenograft tumor model and application provided in the embodiments of the present disclosure can achieve the following technical effects: In the method for constructing a tumor organoid xenograft model of the disclosed embodiment, cells in the active growth period of subculture are selected as xenogeneic inoculation cells. The xenogeneic inoculation cells have strong stemness, strong cell proliferation and differentiation capabilities, and grow most rapidly. Therefore, the organoid cells in the active growth period have better tumorigenicity when inoculated into mice, and have a stable latent period, which improves the success rate of inoculation. At the same time, they can accelerate the growth rate of the inoculated cells in the mouse body, thereby increasing the growth rate of the xenograft model and further shortening the construction cycle and the research and development cycle.
[0012] The xenograft tumor model constructed by the disclosed embodiment can well preserve the target mutations and other pathological characteristics of tumor cells in vivo, has extremely high clinical relevance, and has higher clinical application value. For example, in tumor drug efficacy testing applications, it can more accurately reflect drug efficacy.
[0013] The above general description and the following description are exemplary and explanatory only and are not intended to limit the present application. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] One or more embodiments are exemplarily described by corresponding drawings, which do not limit the embodiments. Elements with the same reference numerals in the drawings are shown as similar elements, and the drawings do not constitute a scale limitation, and wherein: Figure 1 It is a flowchart of a method for constructing a tumor organoid xenograft model provided by an embodiment of the present disclosure; Figure 2 is a photograph of the actively growing breast cancer organoid model collected in Example 2; Figure 3is a graph showing the relationship between xenograft culture time and breast cancer tumor volume at different inoculation doses in Example 2; Figure 4 is a curve diagram showing the relationship between xenograft culture time and breast cancer tumor volume when the organoids are cultured for different culture times at the same inoculation amount in Example 2; Figure 5 is a photograph of the actively growing colon cancer organoid model collected in Example 3; Figure 6 is a graph showing the relationship between xenograft culture time and tumor volume when colon cancer organoids are cultured for different culture times at the same inoculation amount in Example 3; Figure 7 is a photograph of the actively growing pancreatic cancer organoid model collected in Example 4; Figure 8 is a graph showing the relationship between xenograft culture time and tumor volume of pancreatic cancer organoids at different inoculation doses in Example 4; Fig. 9 This is a HE staining characterization result diagram of the pancreatic cancer xenograft tumor model constructed in Example 4 and the passaged pancreatic cancer organoid constructed in Example 1; Fig.10 This is a graph showing the IHC staining results of the pancreatic cancer xenograft tumor model constructed in Example 4 and the passaged pancreatic cancer organoid constructed in Example 1. DETAILED DESCRIPTION
[0015] In order to be able to understand the features and technical contents of the embodiments of the present disclosure in more detail, the implementation of the embodiments of the present disclosure is described in detail below in conjunction with the accompanying drawings. The attached drawings are for reference only and are not used to limit the embodiments of the present disclosure. In the following technical description, for the convenience of explanation, a full understanding of the disclosed embodiments is provided through multiple details. However, one or more embodiments can still be implemented without these details. In other cases, to simplify the drawings, well-known structures and devices can be simplified for display.
[0016] The terms "first", "second", etc. in the specification and claims of the embodiments of the present disclosure and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the terms used in this way can be interchanged where appropriate, so that the embodiments of the embodiments of the present disclosure described herein. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions.
[0017] In the embodiments of the present disclosure, the terms "upper", "lower", "inside", "middle", "outside", "front", "back" and the like indicate directions or positional relationships based on the directions or positional relationships shown in the accompanying drawings. These terms are mainly intended to better describe the embodiments of the present disclosure and their embodiments, and are not intended to limit the indicated devices, elements or components to have a specific direction, or to be constructed and operated in a specific direction. Moreover, in addition to being used to indicate directions or positional relationships, some of the above terms may also be used to indicate other meanings. For example, the term "upper" may also be used to indicate a certain dependency or connection relationship in certain circumstances. For those of ordinary skill in the art, the specific meanings of these terms in the embodiments of the present disclosure can be understood according to specific circumstances.
[0018] In addition, the terms "disposed", "connected", and "fixed" should be understood in a broad sense. For example, "connected" can be a fixed connection, a detachable connection, or an integral structure; it can be a mechanical connection, or an electrical connection; it can be a direct connection, or an indirect connection through an intermediate medium, or it can be an internal connection between two devices, elements, or components. For those of ordinary skill in the art, the specific meanings of the above terms in the embodiments of the present disclosure can be understood according to specific circumstances.
[0019] Unless otherwise stated, the term "plurality" means two or more.
[0020] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present disclosure may be combined with each other.
[0021] Combination Figure 1 As shown, a method for constructing a tumor organoid xenograft model provided in an embodiment of the present disclosure includes: S10. Obtain actively growing passage cells; actively growing passage cells are tumor organoid cells collected when the tumor organoids are cultured to the actively growing stage during in vitro passage culture.
[0022] It is understandable that the in vitro subculture of tumor organoids has a certain subculture cycle, during which the proliferation and differentiation abilities of cells are different. Among them, the growth stage in which cells rapidly proliferate and divide at a rate of 2 times or more is defined as the active growth stage.
[0023] S20. Resuspend the actively growing passaged cells to obtain an inoculated cell mixture.
[0024] S30. Inoculate the inoculated cell mixture into mice for xenotransplantation culture.
[0025] In the construction method of the tumor organoid xenograft model of the disclosed embodiment, cells in the active growth period of in vitro subculture are selected as xenogeneic inoculation cells. The xenogeneic inoculation cells have strong stemness, strong cell proliferation and differentiation ability, and grow most rapidly. Therefore, the organoid cells in the active growth period have better tumorigenicity when inoculated into mice, which can improve the success rate of inoculation, and at the same time can accelerate the growth rate of the inoculated cells in the mouse body, thereby increasing the growth rate of the xenograft tumor model and further shortening the construction cycle and the research and development cycle. Compared with the xenograft culture of tumors using tumor organoid cells collected at the end of the subculture cycle, the construction method of the disclosed embodiment significantly increases the volume of the tumor constructed by the disclosed embodiment under the same transplantation culture time, and the increase is also increasing with the increase of the transplantation culture time. It can be seen that the construction method of the disclosed embodiment makes the tumor grow faster during the xenograft culture process, shortening the research and development cycle and research and development costs.
[0026] The tumors applicable to the method for constructing a tumor organoid xenograft model in the embodiments of the present disclosure include solid tumors; solid tumors include but are not limited to: colon cancer, lung cancer, gastric cancer, liver cancer, bile duct cancer, breast cancer, ovarian cancer, cervical cancer, pancreatic cancer, kidney cancer, melanoma, neuroendocrine tumors and other transplanted tumor models.
[0027] Based on the different parts of the body where the tumor occurs, solid tumors can be divided into the following types of tumors: gynecological reproductive system tumors (including but not limited to breast cancer, ovarian cancer, cervical cancer, etc.), respiratory system tumors (including but not limited to lung cancer, etc.), digestive system tumors (including but not limited to gastric cancer, liver cancer, bile duct cancer, pancreatic cancer, etc.), urinary system tumors (including but not limited to kidney cancer, etc.), and neuroendocrine tumors.
[0028] In the embodiment of the present disclosure, the actively growing passage cells in step S10 are collected when the tumor organoids are cultured in vitro to the active growth stage, that is, the construction of the xenograft model in the embodiment of the present disclosure is based on the construction of an in vitro model of tumor organoids (PDO model). For the construction of the PDO model, it generally takes 2 to 3 weeks from obtaining the tumor tissue during surgery to building the PDO model, and then xenograft culture is performed. The xenograft culture time will also be shorter than the time for traditional PDOX model construction. Therefore, the overall research cycle can be significantly shortened. For example, the overall research cycle can be shortened to 2 to 4 months, so that subsequent applications can be carried out faster, such as tumor drug testing applications, so that guidance on treatment and medication can be given to tumor patients in a shorter time.
[0029] In the disclosed embodiments, the PDO model construction can be expanded in vitro and multiple drugs and multiple concentrations can be tested in the animal model at the same time, which has the advantage of high-throughput screening.
[0030] In step S10 of the disclosed embodiment, the active growth stage is different for different tumor organoid growth characteristics; the growth stage in which cells proliferate and differentiate at a rate of 2 times or more during the subculture process is determined as the active growth stage.
[0031] Optionally, the active growth phase is a growth phase in which cells are cultured to proliferate and differentiate at a rate of 2 times or more. Continuously passaged organoids should conform to the general law of cell growth, that is, they proliferate in the order of lag phase, active growth phase, and stable phase. Organoids that have been passaged by digestion will first experience a lag phase, during which the organoids are mainly single cells or small cell clusters, gradually adapting to the new culture environment, and proliferating relatively slowly. This process generally lasts 2 to 3 days, after which the active growth phase is entered. Therefore, in this embodiment, the active growth phase starts at least on the third day.
[0032] Optionally, the active growth phase is a growth phase starting from at least the third day of culture and in which the cells proliferate and differentiate at a rate of 2 times or more.
[0033] Optionally, the active growth phase is a growth phase within the 3rd to 6th day of culture and the cells proliferate and differentiate at a rate of 2 times or more.
[0034] In some embodiments, obtaining actively growing period passage cells of step S10 includes: S111, digesting the tumor organoids, resuspending them in matrix gel, inoculating them into a culture plate and adding culture medium for in vitro passage culture. S112, collecting the actively growing period tumor organoids when the passage culture reaches the actively growing stage. S113, digesting the actively growing period tumor organoids to obtain actively growing period passage cells. In this embodiment, tumor organoids cultured to the actively growing stage are directly collected during the passage culture process, and the actively growing period passage cells are obtained by digestion and then inoculation. The inoculated cells can maintain better activity and stemness, thereby ensuring the success rate of inoculation.
[0035] Optionally, in step S111, the tumor organoid is a primary tumor organoid. Primary tumor organoids are tumor organoids obtained by culturing tumor tissue in vitro. Specifically, primary tumor organoids are obtained by physically disrupting the tumor tissue, enzymatically hydrolyzing it, resuspending it in matrix gel, inoculating it into a culture plate, and adding culture medium for in vitro culture.
[0036] Optionally, in step S111, the tumor organoid is a passage tumor organoid. The passage tumor organoid is a tumor organoid obtained by passage culture of any generation, for example, a tumor organoid of any generation from the first generation (P1 generation) to the nth generation (Pn generation), wherein the value of n is determined according to the passage ability of the tumor organoid. In this embodiment, the passage tumor organoid can be obtained by sequentially performing primary culture and passage culture, or can be a passage tumor organoid that has been established and frozen, that is, the method for obtaining the passage tumor organoid is not limited, and can be determined according to actual conditions. When the passage tumor organoid uses a frozen passage tumor organoid, after the frozen passage tumor organoid is revived, it is selected whether to perform digestion processing according to actual conditions, and the remaining steps are the same as the aforementioned S111, and at least 2 passage expansion cultures can be performed to meet the cell demand for subsequent xenogeneic inoculation.
[0037] Optionally, the tumor organoids to be passaged are tumor organoids of any generation from the first generation (P1) to the fifth generation (P5).
[0038] Optionally, the passaging tumor organoids are tumor organoids of any generation from the first generation to the third generation.
[0039] Optionally, in step S112, when the subculture reaches the active growth stage, a basal culture medium is used to collect the tumor organoids in the active growth stage to obtain a mixed solution of tumor organoids in the active growth stage. The basal culture medium can be DMEM / F12 basal culture medium.
[0040] Optionally, in step S113, the actively growing tumor organoid mixture is centrifuged to obtain an actively growing tumor organoid precipitate, and then the actively growing tumor organoid precipitate is digested to obtain an actively growing passage cell mixture. In this embodiment, the actively growing passage cells obtained by digestion can be single cells or small cell clusters, for example, small cell clusters formed by 5-10 cells. The digestion solution is not limited.
[0041] Optionally, the step S10 of obtaining actively growing passage cells includes: S121, reviving the frozen Pn generation tumor organoids and expanding the culture; S122, during the expansion process, when the culture reaches the actively growing stage, collecting the actively growing tumor organoids; S123, digesting the actively growing tumor organoids to obtain actively growing passage cells. The frozen Pn generation tumor organoids in this embodiment are obtained by freezing the actively growing passage cells obtained in the aforementioned step S111.
[0042] In step S20, the passage cells in the active growth phase are resuspended to obtain a seeding cell mixture, including: S21, centrifugation to obtain a sediment of the passage cells in the active growth phase; specifically, the passage cell mixture in the active growth phase of step S113 is centrifuged to obtain a sediment of the passage cells in the active growth phase. S22, the passage cell sediment is resuspended in a culture medium, mixed, and then matrix gel is added to obtain a seeding cell mixture. The culture medium and matrix gel are in an equal volume ratio.
[0043] In step S20, the cell density of the obtained inoculated cell mixture can be controlled by cell counting, so as to obtain an inoculated cell mixture with a preset cell density. Moreover, the cell density of the inoculated cell mixture is not limited in this step S20 and can be determined according to actual conditions.
[0044] It can be understood that the inoculation amount N for each mouse is the product of the cell density ρ of the inoculated cell mixture and the inoculation volume V of the inoculated cell mixture for each mouse, that is, N=ρ﹒V. Therefore, according to the cell density of the inoculated cell mixture, the appropriate value can be determined according to the relationship between the inoculation volume V and the inoculation amount N.
[0045] In some embodiments, in step S30, inoculating the inoculated cell mixture into mice comprises: 5 Cells / piece, and the inoculated cell mixture is inoculated into mice. Under the premise of ensuring successful transplantation and growth to the expected size of the tumor, reducing the inoculation amount, that is, reducing the number of inoculated cells, can greatly save the cost of organoid expansion and thus reduce the construction cost. In this example, the minimum inoculation amount can reach 1×10 5 Cells / piece, significantly reducing costs.
[0046] It is understandable that there is no upper limit to the inoculation amount, and a tumor organoid xenograft model can be constructed by increasing the inoculation amount within a cost-permitted and reasonable conventional inoculation amount range.
[0047] Optionally, in step S30, according to 1×10 5 ~1×10 6 Cells / mouse, the cell mixture was inoculated into mice. 6 The inoculation amount of cells / cell is only an example. In practical applications, a tumor organoid xenograft model can be successfully constructed even if the inoculation amount exceeds this upper limit according to the actual situation.
[0048] Optionally, in step S30, according to 1×10 5 ~5×10 5 Cells / mouse, and inoculate the cell mixture into mice.
[0049] Optionally, in step S30, according to 1×10 5 ~2.5×10 5 Cells / mouse, and inoculate the cell mixture into mice.
[0050] Optionally, in step S30, according to 1×10 5 ~2×10 5 Cells / mouse, and inoculate the cell mixture into mice.
[0051] Optionally, in step S30, according to 1×10 5 ~1.5×10 5 Cells / mouse, and inoculate the cell mixture into mice.
[0052] In the disclosed embodiment, in step S30, the inoculated host mice may be nude mice, Nod-Scid mice, or severely immunodeficient mice such as NCG and NSG.
[0053] In the embodiment of the present disclosure, according to the aforementioned not less than 1×10 5 The cell density of the inoculated cell mixture can be determined by combining the inoculation amount of cells / cells with the preset inoculation volume.
[0054] For example, if the inoculation volume for each mouse is 100 μL, the cell density of the inoculated cell mixture should be at least 1×10 6 Cells / mL. Guaranteed to be no less than 1×10 5 Cells / inoculation amount.
[0055] For example, if the inoculation volume for each mouse is 200 μL, the cell density of the inoculated cell mixture should be at least 5×10 5 Cells / mL. Guaranteed to be no less than 1×10 5 Cells / inoculation amount.
[0056] For example, if the inoculation volume for each mouse is 50 μL, the cell density of the inoculated cell mixture should be at least 2×10 6 Cells / mL. Guaranteed to be no less than 1×10 5 Cells / inoculation amount.
[0057] Optionally, the cell mixture is inoculated at a cell density of at least 5 × 10 5 ~2×10 6 Cells / mL. The inoculation volume was 50 μL to 200 μL to ensure that the inoculation volume per mouse reached 1×10 5 Cells / cells.
[0058] Optionally, the cell mixture is inoculated at a cell density of at least 5 × 10 5 ~1×10 6 Cells / mL. The inoculation volume was within the range of 100 μL to 200 μL to ensure that the inoculation volume per mouse reached 1×10 5 Cells / cells.
[0059] In the construction method of the disclosed embodiment, after completing step S30, the mental state, diet, activities, etc. of the mice are observed every week; the tumor volume of the mice is measured once a week with a vernier caliper, and the volume formula V=short diameter*short diameter*long diameter / 2, and the volume ≥80mm 3 Considered as a tumor.
[0060] The disclosed embodiments also provide a xenograft tumor model, which is obtained by constructing any of the aforementioned methods for constructing a tumor organoid xenograft model.
[0061] The xenograft tumor model constructed by the disclosed embodiment has a fast growth rate and a short tumor formation time, which shortens the construction cycle, thereby shortening the subsequent research and development cycle and reducing costs. In addition, the xenograft tumor model has good biomimetic properties and can well preserve the target mutations and other pathological characteristics of tumor cells in the body. It has extremely high clinical relevance and higher clinical application value. For example, in tumor efficacy testing applications, it can more accurately reflect the efficacy of the drug.
[0062] The disclosed embodiments also provide the application of xenograft tumor models in the evaluation of the efficacy of tumor drugs.
[0063] In the application of the disclosed embodiments, since the construction period of the xenograft tumor model is shortened, the overall period for evaluating the efficacy of tumor drugs is shortened, thereby reducing the application cost.
[0064] The following is a specific example to illustrate the method for constructing a tumor organoid xenograft model according to the embodiment of the present disclosure.
[0065] Example 1 A method for constructing a tumor organoid comprises the following steps: S1011. Wash the tumor tissue sample by shaking, and then use ophthalmic scissors to break the tissue sample block into fine tissue fragments to obtain a paste-like tissue sample, and control the diameter of the tissue fragments to be about 1 mm.
[0066] S1012. Collect the paste tissue sample into a conical centrifuge tube and add enzymatic hydrolysis solution. Perform full enzymatic hydrolysis in a constant temperature shaker at 37°C and 200-250 rpm for 10-15 minutes. Observe under a microscope every 5 minutes. Stop the constant temperature shaking when a large number of cell clumps are found in the suspension to obtain an enzymatic cell mixture.
[0067] S1013. Add organoid washing solution to the tissue cell enzymatic hydrolysis mixture to resuspend the enzymatic cells, mix thoroughly, let stand to allow large clumps to settle, collect the supernatant and transfer it to a new centrifuge tube; then add organoid washing solution to the large clumps and repeat the above resuspension, mixing and standing, collect the supernatant and transfer it to a new centrifuge tube. Repeat multiple times and transfer the supernatants collected multiple times to the same new centrifuge tube.
[0068] S1014. Centrifuge the remaining tissue cell suspension in the conical centrifuge tube at 4°C and 400 g for 5 min to obtain a cell pellet. It is necessary to ensure that there are no red blood cells in the cell pellet. If there are red blood cells in the cell pellet, add red blood cell lysis buffer to the cell pellet, incubate at room temperature, resuspend with washing buffer, and then centrifuge to obtain a cell pellet.
[0069] S1015. Resuspend the cell pellet in tumor organoid culture medium (same volume as the cell pellet), mix well, and then add 2 times the volume of matrix gel to resuspend and obtain a cell gel suspension.
[0070] S1016. Inoculate the cell gel suspension (e.g., 50 μL per well) on a cell culture plate (e.g., a 24-well cell culture plate) and solidify at 37°C for 10 min.
[0071] S1017. After the gel is solidified, add 500 μL of tumor organoid culture medium containing 1× anti-apoptotic factor to each well for primary culture to obtain primary tumor organoids. During the primary culture process, the medium is changed every 3 to 4 days. No anti-apoptotic factor is added for subsequent medium changes, and the growth status of the organoids is recorded and observed.
[0072] S1018. Digest the primary tumor organoids to obtain a digested cell mixture in the form of single cells or small cell clusters; then add matrix gel to the digested cell mixture and resuspend it to obtain a passage cell gel suspension, and then inoculate the passage cell gel suspension onto a cell culture plate in the form of gel droplets and solidify at 37°C for 10 min. After solidification, add tumor organoid culture medium to each well for subculture to obtain passage tumor organoids.
[0073] In this embodiment 1, by using different types of tumor tissues in step S1011, corresponding types of tumor organoids can be constructed.
[0074] Constructing breast cancer organoids: In step S1011, the tumor tissue is breast cancer tumor tissue, and in step S1017, primary breast cancer organoids are obtained by primary culture; in step S1018, subculture is performed to obtain subculture breast cancer organoids, and the subculture cycle is 6-8 days.
[0075] Constructing colon cancer organoids: In step S1011, the tumor tissue is colon cancer tumor tissue, and in step S1017, the primary colon cancer organoid model is obtained by primary culture; in step S1018, the subculture is used to obtain the subculture colon cancer organoid, and the subculture cycle is 7-9 days.
[0076] Constructing pancreatic cancer organoids: in step S1011, the tumor tissue is pancreatic cancer tumor tissue, and in step S1017, the primary pancreatic cancer organoid model is obtained by primary culture; in step S1018, the subculture is performed to obtain the subculture pancreatic cancer organoid, and the subculture cycle is 7-9 days.
[0077] Example 2 A method for constructing a tumor organoid xenograft model (xenograft breast cancer tumor model), comprising: S102. The primary breast cancer organoids constructed in Example 1 are digested, resuspended in matrix gel, inoculated into a culture plate, and culture medium is added for in vitro subculture. On the third day of subculture (active growth phase), the actively growing tumor organoids are collected. The actively growing tumor organoids are digested to obtain actively growing subculture cells.
[0078] S202, centrifugally separating the actively growing passage cells to obtain actively growing passage cell precipitates, resuspending the actively growing passage cell precipitates with culture medium, mixing, and then adding a volume of matrix gel equal to that of the culture medium to obtain an inoculated cell mixture.
[0079] S302, according to no less than 1×10 5 The inoculation amount of cells / mouse was 100 μg / mL, and the inoculated cell mixture was inoculated into nude mice for xenograft culture to obtain a xenograft breast cancer tumor model.
[0080] In this Example 2, the mental state, diet, and activities of the mice were observed weekly. The tumor volume of the mice was measured once a week using a vernier caliper. The volume formula was V = short diameter * short diameter * long diameter / 2. The tumor formation standard was a volume ≥ 80 mm. 3 .
[0081] The photo of the tumor organoid model in the active growth phase collected in step S202 of this embodiment 2 is as follows Figure 2 As shown, it can be seen that in the actively growing tumor organoid model, the organoids have a certain spatial structure, are nearly round, translucent cell spheres in morphology, and have a certain heterogeneity.
[0082] In this Example 2, the inoculum size was 1×10 5 Cells / pc, 2.5×10 5 Cells / 5×10 5The tumor volume of xenograft cultures was measured at 35 days (5 weeks) of culture. Figure 3 The curve diagram of the relationship between xenograft culture time and tumor volume is shown in Figure 2. Figure 3 It can be seen that the incubation period (the time from inoculation to the measurable tumor volume) of tumors obtained by different inoculation doses is 0-7 days; under the same culture time, the tumor volume increases with the increase of inoculation dose, and when the inoculation dose is 1×10 5 Cells / cell, the tumor volume can reach about 1000 mm3 after 35 days (5 weeks) of inoculation. 3 , which can meet the needs of drug efficacy testing. Figure 3 The tumor volume in the figure is the average volume of multiple tumor models in the same batch culture.
[0083] In this embodiment 2, a comparative experiment was also conducted, and the comparative experiment was as follows: in step S102, during the in vitro subculture process, when the subculture reaches the 7th day (the entire subculture cycle), the subculture tumor organoids are collected and digested to obtain subculture cells. In step S202, the subculture cells in the active growth phase are replaced with the aforementioned subculture cells. The other steps and parameters are the same as those in this embodiment 2.
[0084] The inoculum size was 1×10 5 Cells / cells as an example, the volume of the tumor model obtained by xenograft culture was measured. The measurement results are as follows Figure 4 The curve shown by “—▲—” in the figure. Figure 4 The “—●—” indicates that the inoculum size in Example 2 is 1×10 5 Cells / cell xenograft culture tumor volume growth curve. It can be seen that under the premise of maintaining the same inoculation amount, the transplanted tumor constructed according to the method of Example 2 grows rapidly. On the 35th day after inoculation, the volume of the tumor constructed in Example 2 increases to nearly 2 times that of the control experiment. It can be seen that the construction method of Example 2 makes the tumor grow faster during the xenograft culture process, which can reduce the R&D cycle and R&D costs.
[0085] In the construction of the xenograft breast cancer tumor model in Example 2, the cell inoculation amount of the organoid only needs to reach 1×10 5 Cells / cells can construct a PDOX model with stable latency and rapid growth.
[0086] In the process of constructing the xenograft breast cancer tumor model of this Example 2, the tumor model of the required volume can be obtained after 5 weeks of xenograft culture. Adding the time required to obtain the active growth phase passage cells (about 2 weeks to 3 weeks), the construction period of the xenograft breast cancer tumor model is about 7 weeks to 8 weeks. It can be seen that the overall construction period is significantly shortened.
[0087] Example 3 A method for constructing a tumor organoid xenograft model (xenograft colon cancer tumor model), comprising: S103. The primary colon cancer organoid model constructed in Example 1 is digested, resuspended in matrix gel, inoculated into a culture plate, and culture medium is added for in vitro subculture. On the 4th day of subculture (active growth stage), the colon cancer tumor organoids in the active growth stage are collected. The colon cancer tumor organoids in the active growth stage are digested to obtain a cell digestion mixture of colon cancer organoids in the active growth stage.
[0088] S203. Centrifuge the actively growing colon cancer organoid cell digestion mixture to obtain an actively growing colon cancer organoid cell pellet, resuspend the actively growing colon cancer organoid cell pellet with culture medium, mix well, and then add a volume of matrix gel equal to that of the culture medium to obtain an inoculated cell mixture.
[0089] S303, according to no less than 1×10 5 Cells / mouse, and the cell mixture was inoculated into NCG mice for xenograft culture.
[0090] In this Example 3, the mental state, diet, and activities of the mice were observed weekly. The tumor volume of the mice was measured once a week using a vernier caliper. The volume formula was V = short diameter * short diameter * long diameter / 2. The tumor formation standard was a volume ≥ 80 mm 3 .
[0091] The photo of the tumor organoid model in the active growth phase collected in step S103 of this embodiment 3 is as follows Figure 5 As shown, it can be seen that in the actively growing tumor organoid model, the organoids have a certain spatial structure, are nearly round, translucent cell spheres in morphology, and have a certain heterogeneity.
[0092] In this Example 3, the specific inoculum size is 5×10 5 The tumor volume of xenograft cultures was measured at 10 cells / well after 63 days (9 weeks). Figure 6 The “—■—” in the figure shows the relationship between xenograft culture time and tumor volume.
[0093] In this Example 3, a comparative experiment was also conducted. The comparative experiment is as follows: In step S103, during the in vitro subculture process, when the subculture reaches the 8th day (the entire subculture cycle), the subculture tumor organoids are collected and digested to obtain subculture cells. In step S203, the subculture cells in the active growth phase are replaced with the aforementioned subculture cells. The other steps and parameters are the same as in this Example 3. In this comparative experiment, the inoculation amount is 5×105 The tumor volume of xenograft cultures of cells / cells was measured, and the measurement results were as follows Figure 6 The growth curve is shown in “—□—”.
[0094] By comparison Figure 6 From the two growth curves in the figure, it can be seen that, under the premise of maintaining the same inoculation amount, the incubation period of the transplanted tumor constructed according to the method described in Example 3 is 7 to 14 days, and the incubation period of the transplanted tumor constructed by the comparative test method is 14 to 28 days; on the 58th day after inoculation, the volume of the tumor constructed by the method described in this example can be increased to 2-3 times that of the comparative experiment. It can be seen that the construction method of Example 3 makes the tumor incubation period shorter and grows faster during the xenotransplantation culture process, which can reduce the R&D cycle and R&D cost.
[0095] In the process of constructing the xenograft colon cancer tumor model of this Example 3, the tumor model of the required volume can be obtained after 8 weeks of xenograft culture. Adding the time required to obtain the active growth phase passage cells (about 3 weeks to 5 weeks), the construction period of the xenograft colon cancer tumor model is about 11 weeks to 13 weeks. It can be seen that the overall construction period is significantly shortened.
[0096] Example 4 A method for constructing a tumor organoid xenograft model (xenograft pancreatic cancer tumor model), comprising: S104. The primary pancreatic cancer organoid model constructed in Example 1 is digested, resuspended in matrix gel, inoculated into a culture plate, and culture medium is added for in vitro subculture. On the fifth day of subculture (active growth stage), the actively growing tumor organoids are collected. The actively growing pancreatic cancer tumor organoids are digested to obtain an actively growing pancreatic cancer organoid cell digestion mixture.
[0097] S204, centrifugally separating the pancreatic cancer organoid cell digestion mixture in the active growth phase to obtain the cell pellet in the active growth phase. Resuspend the pancreatic cancer organoid cell pellet in the active growth phase with the culture medium, mix well, and then add the matrix gel in an equal volume to the culture medium to obtain the inoculated cell mixture.
[0098] S304, according to no less than 1×10 5 The inoculation amount of cells / mouse was 100 μg / mL, and the inoculated cell mixture was inoculated into nude mice for xenograft culture.
[0099] In this Example 4, the mental state, diet, and activities of the mice were observed weekly. The tumor volume of the mice was measured once a week using a vernier caliper. The volume formula was V = short diameter * short diameter * long diameter / 2. The tumor formation standard was a volume ≥ 80 mm. 3 .
[0100] The photo of the tumor organoid model in the active growth phase collected in step S204 of this embodiment 4 is as follows Figure 7 As shown, it can be seen that in the actively growing tumor organoid model, the organoids have a certain spatial structure, are nearly round, translucent cell spheres in morphology, and have a certain heterogeneity.
[0101] In this Example 4, the specific inoculum size is 1×10 5 Cells / pc, 2.5×10 5 Cells / 5×10 5 The tumor volume of xenograft cultures was measured at 56 days (8 weeks) of culture. Figure 8 Figure 2 is a graph showing the relationship between xenograft culture time and tumor volume. Figure 8 It can be seen that the incubation period of tumors obtained by different inoculation amounts is 0 to 7 days; under the same culture time, the tumor volume increases with the increase of inoculation amount, and when the inoculation amount is 1×10 5 Cells / cell, the tumor volume can exceed 600 mm at 56 days (8 weeks) after inoculation. 3 , which can meet the needs of drug efficacy testing. Figure 8 The tumor volume in the figure is the average volume of multiple tumor models in the same batch of culture.
[0102] In the construction of the xenograft pancreatic cancer tumor model of Example 4, the cell inoculation amount of the pancreatic cancer organoid only needs to reach 1×10 5 Cells / cells can construct a PDOX model with stable latency and rapid growth.
[0103] In the process of constructing the xenograft pancreatic cancer tumor model of this Example 4, the tumor model of the required volume can be obtained after 8 weeks of xenograft culture. Adding the time required to obtain the active growth phase passage cells (about 3 weeks to 5 weeks), the construction period of the xenograft pancreatic cancer tumor model is about 11 weeks to 13 weeks. It can be seen that the overall construction period is significantly shortened.
[0104] In the disclosed examples, HE staining and IHC staining were performed on the xenograft pancreatic cancer tumor model (abbreviated as PDOX) constructed in Example 4 to observe the structural characteristics of the tumor model and identify the consistency of the target protein. At the same time, HE staining and IHC staining were also performed on the tumor tissue (abbreviated as Tissue) obtained in Example 4 and the constructed passaged pancreatic cancer organoids (abbreviated as Organoids). The characterization results are as follows: Fig. 9 HE staining results shown and Fig.10The IHC staining characterization results are shown. It can be seen that both the organoid morphology and target expression are consistent. The PDOX model can well preserve the target mutations and other pathological characteristics of tumor cells in vivo, has extremely high clinical relevance, and has higher clinical application value. For example, in tumor efficacy testing applications, it can more accurately reflect the efficacy of the drug.
[0105] In Examples 2 to 4 of the disclosed embodiments, the inoculation volume of the cell mixture for each mouse is not limited, as long as the inoculation amount is guaranteed. As an example, the inoculation volume of the cell mixture for each mouse is 100 μL or 200 μL.
[0106] The above description and the accompanying drawings sufficiently illustrate the embodiments of the present disclosure to enable those skilled in the art to practice them. Other embodiments may include structural and other changes. The embodiments represent only possible variations. Unless explicitly required, individual components and functions are optional, and the order of operations may vary. Portions and features of some embodiments may be included in or replace portions and features of other embodiments. The embodiments of the present disclosure are not limited to the structures described above and shown in the accompanying drawings, and various modifications and changes may be made without departing from the scope thereof. The scope of the present disclosure is limited only by the appended claims.
Claims
1. A method for constructing a tumor organoid xenograft model, characterized in that: include: Obtaining actively growing passage cells; wherein the actively growing passage cells are obtained by digesting and processing tumor organoids collected when the tumor organoids are cultured to the actively growing stage during in vitro passage culture; Resuspend the passaged cells in the active growth phase to obtain an inoculated cell mixture; The cell mixture was inoculated into mice.
2. The construction method according to claim 1, characterized in that: Inoculate mice with a cell mixture that includes: According to no less than 1×10 5 Cells / mouse inoculation amount, inoculate the cell mixture into mice.
3. The construction method according to claim 2, characterized in that: According to 1×10 5 ~5×10 5 Cells / mouse, and inoculate the cell mixture into mice.
4. The construction method according to claim 1, characterized in that: Resuspend the actively growing passaged cells to obtain a cell inoculation mixture; including: Centrifuge to obtain the pellet of subculture cells in the active growth phase; The cell pellet in the active growth phase was resuspended in culture medium, mixed evenly, and then matrix gel was added to obtain a cell inoculation mixture.
5. The construction method according to claim 4, characterized in that: The cell density of the inoculated cell mixture should be at least 5×10 5 ~1×10 6 Cells / mL.
6. The construction method according to any one of claims 1 to 5, characterized in that: Obtain actively growing cells, including: After digesting the tumor organoids and resuspending them in matrix gel, they were seeded into culture plates and culture medium was added for in vitro subculture; When the subculture reaches the active growth stage, the actively growing tumor organoids are collected; Actively growing tumor organoids are digested to obtain actively growing tumor organoid cells.
7. The construction method according to claim 6, characterized in that: Tumor organoids are primary tumor organoids or tumor organoids that have been established and passaged; Among them, primary tumor organoids are tumor organoids obtained by culturing tumor tissue in vitro; established and passaged tumor organoids are tumor organoids obtained by culturing at any generation.
8. The construction method according to any one of claims 1 to 5, characterized in that: The active growth phase is a growth phase that starts at least from the third day of culture and in which cells proliferate and differentiate at a rate of 2 times or more.
9. A xenograft tumor model, characterized in that The tumor organoid xenograft model is obtained by the method for constructing the tumor organoid xenograft model as described in any one of claims 1 to 8.
10. Use of a xenograft tumor model as claimed in claim 9 in evaluating the efficacy of tumor drugs.
Citation Information
Patent Citations
Method for detecting semi-inhibitory concentration of organoid drug by adopting fluorescent staining
CN116377013A
Human colorectal cancer primary lesion and liver metastatic lesion paired organoid cell line as well as culture method and application thereof
CN116463291A
Construction method and application of patient-derived transplanted tumor organ model PDXO
CN117004572A
Drug screening method based on breast cancer organoid and organoid transplantation tumor mouse model
CN117398481A
Method for preparing HER2 positive quality control material through organoid xenograft tumor
CN117706080A
